Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy [SUpplemental Patient dMd assessMents Investigating ouTcomes (SUMMIT)]

NCT06564974 is registered in ClinicalTrials.gov with Catalyst Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06564974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06564974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy [SUpplemental Patient dMd assessMents Investigating ouTcomes (SUMMIT)]
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Phase
Observational
Overall status
Recruiting
Start date
September 25, 2024
Completion date
February 29, 2032
Enrollment
250 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy